胰腺癌术后辅助药物治疗的研究进展

胰腺癌是一种致死性极高的恶性肿瘤,其5年生存率不到8%。可行根治性手术的胰腺癌患者较未行手术者预后有显著差异,单纯的手术治疗仅能将胰腺癌5年生存率提高至10%左右,究其原因主要是单纯手术后复发、转移的几率仍然极高,且复发、转移后患者生活质量欠佳,预后极差,远期生存时间短。因此,寻求胰腺癌术后更加有效的辅助治疗药物或者方案,并进行规范、合理、综合的药物治疗,控制微转移,对防止和延迟复发意义重大,该研究领域也是近年来针对胰腺癌研究的重点方向。本文基于近年来胰腺癌术后治疗的研究进展做一综述。探索胰腺癌术后不同药物、不同治疗方案下的生存获益情况及胰腺癌术后治疗的药物发展趋势,为胰腺癌术后治疗提供有价值的参考。

Advances in research on adjuvant drug threapy for postoperative pancreatic cancer

Pancreatic cancer is a highly lethal malignant tumor with a 5-year survival rate less than 8%.The prognosis of patients with pancreatic cancer who can undergo radical surgery is significantly different from that of those who have not undergone surgery.Simple surgical treatment can only increase the 5-year survival rate of pancreatic cancer to about 10%.The main reason is that the recurrence and metastasis rates are still extremely high after surgery alone,and the quality of patient life with recurrence and metastasis is poor,their prognosis is extremely poor,and the long-term survival time is short.Therefore,it is of great significance to seek more effective adjuvant therapy or regimen for pancreatic cancer surgery,and to carry out standardized,rational and comprehensive drug therapy,to control micrometastasis,and to prevent and delay recurrence.This research field is also the focus on research direction about pancreatic cancer in recent years.This article is based on the recent research and development of postoperative treatment of pancreatic cancer,exploring survival benefit of different drugs and different treatment options after pancreatic cancer surgery and the development trend of postoperative treatment of pancreatic cancer,providing a valuable reference for postoperative treatment of pancreatic cancer.